|
|
CSF2RA |
colony stimulating factor 2 receptor subunit alpha |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- Surfactant metabolism
- Defective CSF2RB causes SMDP5
- Defective CSF2RA causes SMDP4
- Interleukin receptor SHC signaling
|
- Sargramostim
- KB002
- Regramostim
- Foreskin fibroblast (neonatal)
- Foreskin keratinocyte (neonatal)
- Clove oil
|
|
|
|
FCGR2A |
Fc fragment of IgG receptor IIa |
- FCGR activation
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Role of phospholipids in phagocytosis
- Neutrophil degranulation
- FCGR3A-mediated IL10 synthesis
|
- Cetuximab
- Etanercept
- Human immunoglobulin G
- Abciximab
- Alemtuzumab
- Daclizumab
- Bevacizumab
- Catumaxomab
- Sarilumab
|
- Systemic lupus erythematosus
|
|
|
GRIA3 |
glutamate ionotropic receptor AMPA type subunit 3 |
- Activation of AMPA receptors
- Trafficking of AMPA receptors
- Trafficking of GluR2-containing AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Synaptic adhesion-like molecules
|
- Glutamic acid
- Butabarbital
- Ethanol
- Lithium cation
- Aniracetam
- Talampanel
- CX-717
- Fluciclovine (18F)
- Lithium citrate
- Lithium succinate
- Lithium carbonate
|
- Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
|
|
|
IL1B |
interleukin 1 beta |
- Interleukin-1 processing
- CLEC7A/inflammasome pathway
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-1 signaling
- Purinergic signaling in leishmaniasis infection
|
- Donepezil
- Minocycline
- VP025
- Gallium nitrate
- Talmapimod
- Etiprednol dicloacetate
- VX-702
- VX-765
- Andrographolide
- Canakinumab
- Rilonacept
- Foreskin keratinocyte (neonatal)
- Binimetinib
- Gevokizumab
- Dilmapimod
|
|
|
|
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
- Platelet degranulation
- Cell surface interactions at the vascular wall
- PECAM1 interactions
- Integrin cell surface interactions
- Platelet sensitization by LDL
- Neutrophil degranulation
|
|
|
|
|
RASA1 |
RAS p21 protein activator 1 |
- Downstream signal transduction
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- VEGFR2 mediated cell proliferation
- Regulation of RAS by GAPs
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
- RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
|
|
|
BCAR1 |
BCAR1 scaffold protein, Cas family member |
- Downstream signal transduction
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
|
|
|
IL2RB |
interleukin 2 receptor subunit beta |
- RAF/MAP kinase cascade
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Interleukin receptor SHC signaling
|
- Denileukin diftitox
- Aldesleukin
- Basiliximab
- Daclizumab
|
|
|
|
INPP5D |
inositol polyphosphate-5-phosphatase D |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Downstream TCR signaling
- PECAM1 interactions
- Interleukin receptor SHC signaling
|
|
|
|
|
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
- GPVI-mediated activation cascade
- Synthesis of PIPs at the plasma membrane
- G beta:gamma signalling through PI3Kgamma
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
|
- Staurosporine
- Myricetin
- LY-294002
- Quercetin
- 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
- XL765
- TG100-115
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide
- 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
- Wortmannin
- 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- Duvelisib
- Fostamatinib
|
|
|
|
CD22 |
CD22 molecule |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- CD22 mediated BCR regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Epratuzumab
- Inotuzumab ozogamicin
- Moxetumomab Pasudotox
|
|
|
|
EVL |
Enah/Vasp-like |
- Generation of second messenger molecules
- Signaling by ROBO receptors
- Signaling by ROBO receptors
- RHO GTPases Activate Formins
|
|
|
|
|
HNRNPK |
heterogeneous nuclear ribonucleoprotein K |
- SUMOylation of RNA binding proteins
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
- HCMV Late Events
|
- Artenimol
- Phenethyl Isothiocyanate
|
|
|
|
IL7R |
interleukin 7 receptor |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
|
PRKDC |
protein kinase, DNA-activated, catalytic subunit |
- Cytosolic sensors of pathogen-associated DNA
- IRF3-mediated induction of type I IFN
- Nonhomologous End-Joining (NHEJ)
- E3 ubiquitin ligases ubiquitinate target proteins
|
|
|
|
|
RGS16 |
regulator of G protein signaling 16 |
- G alpha (q) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- G alpha (z) signalling events
|
|
|
|
|
SLC4A1 |
solute carrier family 4 member 1 (Diego blood group) |
- Erythrocytes take up carbon dioxide and release oxygen
- Erythrocytes take up oxygen and release carbon dioxide
- Bicarbonate transporters
- Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)
|
|
- Hereditary elliptocytosis (HE)
- Hereditary spherocytosis (SPH)
- Hereditary stomatocytosis (HSt); Dehydrated hereditary stomatocytosis (DHS); Overhydrated hereditary stomatocytosis (OHS); Familial pseudohyperkalemia (FP)
- Distal renal tubular acidosis (RTA type 1)
|
|
|
SPHK1 |
sphingosine kinase 1 |
- Sphingolipid de novo biosynthesis
- Association of TriC/CCT with target proteins during biosynthesis
- VEGFR2 mediated cell proliferation
- Extra-nuclear estrogen signaling
|
|
|
|
|
TEC |
tec protein tyrosine kinase |
- Signaling by SCF-KIT
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Interleukin-3, Interleukin-5 and GM-CSF signaling
|
- Fostamatinib
- Zanubrutinib
|
|
|
|
TRAT1 |
T cell receptor associated transmembrane adaptor 1 |
- PIP3 activates AKT signaling
- Downstream TCR signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|